Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver

	Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver
	Lehmann, Rainer 1,2; Franken, Holger 3; Dammeier, Sascha 4; Rosenbaum, Lars 3; Kantartzis, Konstantinos 1,2; Peter, Andreas 1,2; Zell, Andreas 3; Adam, Patrick 5; Li, Jia 6; Xu, Guowang 6
刊名	diabetes care
	2013-08-01
卷号	36 期号:8 页码:2331-2338
通讯作者	norbert stefan
产权排序	待补充
合作状况	英
英文摘要	objectivenonalcoholic fatty liver (nafl) is thought to contribute to insulin resistance and its metabolic complications. however, some individuals with nafl remain insulin sensitive. mechanisms involved in the susceptibility to develop insulin resistance in humans with nafl are largely unknown. we investigated circulating markers and mechanisms of a metabolically benign and malignant nafl by applying a metabolomic approach.research design and methodsa total of 265 metabolites were analyzed before and after a 9-month lifestyle intervention in plasma from 20 insulin-sensitive and 20 insulin-resistant subjects with nafl. the relevant plasma metabolites were then tested for relationships with insulin sensitivity in 17 subjects without nafl and in plasma from 29 subjects with liver tissue samples.resultsthe best separation of the insulin-sensitive from the insulin-resistant nafl group was achieved by a metabolite pattern including the branched-chain amino acids leucine and isoleucine, ornithine, the acylcarnitines c3:0-, c16:0-, and c18:0-carnitine, and lysophosphatidylcholine (lyso-pc) c16:0 (area under the roc curve, 0.77 [p = 0.00023] at baseline and 0.80 [p = 0.000019] at follow-up). among the individual metabolites, predominantly higher levels of lyso-pc c16:0, both at baseline (p = 0.0039) and at follow-up (p = 0.001), were found in the insulin-sensitive compared with the insulin-resistant subjects. in the non-nafl groups, no differences in lyso-pc c16:0 levels were found between the insulin-sensitive and insulin-resistant subjects, and these relationships were replicated in plasma from subjects with liver tissue samples.conclusionsfrom a plasma metabolomic pattern, particularly lyso-pcs are able to separate metabolically benign from malignant nafl in humans and may highlight important pathways in the pathogenesis of fatty liver-induced insulin resistance.
学科主题	物理化学
WOS标题词	science & technology ; life sciences & biomedicine
类目[WOS]	endocrinology & metabolism
研究领域[WOS]	endocrinology & metabolism
关键词[WOS]	regulatory t-cells ; life-style intervention ; insulin-resistance ; hepatic steatosis ; disease ; obesity ; homeostasis ; risk ; steatohepatitis ; mechanisms
收录类别	SCI
资助信息	6，9
原文出处	2338
语种	英语
WOS记录号	WOS:000327252600049
公开日期	2014-09-11
内容类型	期刊论文
源URL	[http://159.226.238.44/handle/321008/119130]
专题	大连化学物理研究所_中国科学院大连化学物理研究所
作者单位	1.Univ Hosp Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Med Nephrol & Clin C, Tubingen, Germany 2.Univ Tubingen, Inst Diabet Res & Metab Dis, Tubingen, Germany 3.Univ Tubingen, Ctr Bioinformat, Tubingen, Germany 4.Univ Tubingen, Med Proteome Ctr, Inst Ophthalm Res, Tubingen, Germany 5.Univ Tubingen, Inst Pathol, Tubingen, Germany 6.Chinese Acad Sci, Dalian Inst Chem Phys, CAS Key Lab Separat Sci Analyt Chem, Dalian, Peoples R China 7.Univ Tubingen, Dept Gen Visceral & Transplant Surg, Tubingen, Germany 8.Univ Tubingen, Sect Expt Radiol, Tubingen, Germany 9.Helmholtz Zentrum, Inst Expt Genet, Munich, Germany 10.Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
推荐引用方式 GB/T 7714	Lehmann, Rainer,Franken, Holger,Dammeier, Sascha,et al. Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver[J]. diabetes care,2013,36(8):2331-2338.
APA	Lehmann, Rainer.,Franken, Holger.,Dammeier, Sascha.,Rosenbaum, Lars.,Kantartzis, Konstantinos.,...&Stefan, Norbert.(2013).Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver.diabetes care,36(8),2331-2338.
MLA	Lehmann, Rainer,et al."Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver".diabetes care 36.8(2013):2331-2338.